In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI
This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a noninvasive imaging biomarker of inflammation.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Diagnostic (ferumoxytol-enhanced MRI)
- procedure: Surgery
- drug: Ferumoxytol
- other: Tissue Analysis
Eligibility
Inclusion Criteria:
- Any patient with suspected malignant brain tumor on diagnostic MR imaging who will
undergo a resection
Exclusion Criteria:
- Informed consent cannot be obtained either from the patient or legal representative
- Severe coexisting or terminal systemic disease that may interfere with the conduct of
the study
- Contraindication to MRI (metal implants)
- Hemosiderosis/hemochromatosis
- Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
parenteral iron, or any other etiology
- Known hypersensitivity to ferumoxytol or any of its components
- Pregnant patients
Ages Eligible for Study
2 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Paymon Rezaii
650-743-8336
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.
